Investment case
SPDR S&P Biotech ETF
XBI · 36 developments mapped · last assessed 2026-09-29
Market Ontology has mapped 36 macro, policy, and market developments to SPDR S&P Biotech ETF since 2026-08-12. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for XBI yet, so no modelled value is shown. The XBI valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run XBI on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 Firms
Increased investor sentiment and capital flow into the biotechnology sector, particularly those focused on rare diseases and neurology.
· Moves sector growth outlook, investor risk appetite
- Main threat
Ionis Pharmaceuticals faces pipeline pressure after pelacarsen and eplontersen trial setbacks
Sector sentiment. Significant setbacks for a prominent biotech company like Ionis can weigh on broader investor confidence in the sector, especially for companies with similar pipeline-driven risk profiles.
· Moves overall sector risk premium, investor appetite for high risk, high reward biotech investments
- Open question
Electra Therapeutics Sets Nasdaq IPO Terms to Raise Up to $347M
General sentiment towards the biotech sector and potential for new constituent.
· Moves sector wide investor confidence, etf inflows/outflows
What changed, by assumption
- 2026-08-26Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 Firms
- 2026-08-21Werewolf Therapeutics and Ambros Therapeutics announce merger agreement and concurrent $150 million private placement
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/Share
- 2026-09-25ADARx Pharma Prices Upsized $446.3M IPO at $17 on Nasdaq
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per Share
- 2026-09-03NEJM Publishes Revolution Medicines Daraxonrasib NSCLC Data: 42% ORR, 16.0 Mo Survival
- 2026-09-12FDA Approves Isembyld for Spinal Muscular Atrophy
- 2026-08-26FDA Approves Revolution Medicines' RASONQUE as First Targeted RAS Inhibitor
- 2026-09-21Bristol Myers Squibb Posts $12.9B Revenue as Growth Portfolio Hits 60%
- 2026-09-21Ionis slides over 40% year-to-date following late-stage clinical setbacks
- 2026-09-21Ionis Pharmaceuticals trades down 40% following late-stage clinical setbacks
- 2026-09-02TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-29 | Oncolytics Biotech Announces Publication of Pelareorep Data in Liver Cancer | Bullish | 1-3m | 0.10 |
| 2026-09-29 | Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial | Bullish | 1-3m | 0.10 |
| 2026-09-25 | ADARx Pharma Prices Upsized $446.3M IPO at $17 on Nasdaq | Bullish | 1-5d | 0.40 |
| 2026-09-25 | ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per Share | Bullish | intraday | 0.30 |
| 2026-09-25 | ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17 | Bullish | 1-5d | 0.60 |
| 2026-09-25 | ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/Share | Bullish | 1-3m | 0.60 |
| 2026-09-24 | Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology | watch | 1-3m | 0.20 |
| 2026-09-23 | Longeveron Announces Exploration of All Options to Maximize Shareholder Value Following Phase 2b Trial Results | Bearish | 1-5d | 0.20 |
| 2026-09-21 | Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study | Bullish | 1-5d | 0.10 |
| 2026-09-21 | Ionis slides over 40% year-to-date following late-stage clinical setbacks | Bearish | 1-5d | 0.20 |
| 2026-09-21 | Bristol Myers Squibb Posts $12.9B Revenue as Growth Portfolio Hits 60% | Bullish | 1-3m | 0.40 |
| 2026-09-21 | Ionis Pharmaceuticals faces pipeline pressure after pelacarsen and eplontersen trial setbacks | Bearish | 1-3m | 0.40 |